• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溴结构域的结构特征与抑制剂

Structural features and inhibitors of bromodomains.

作者信息

Meslamani Jamel, Smith Steven G, Sanchez Roberto, Zhou Ming-Ming

机构信息

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, United States.

Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, United States.

出版信息

Drug Discov Today Technol. 2016 Mar;19:3-15. doi: 10.1016/j.ddtec.2016.09.001. Epub 2016 Sep 22.

DOI:10.1016/j.ddtec.2016.09.001
PMID:27769355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5325140/
Abstract

Bromodomains are conserved structural modules responsible for recognizing acetylated-lysine residues on histone tails and other transcription-associated proteins, such as transcription factors and co-factors. Owing to their important functions in the regulation of ordered gene transcription in chromatin, bromodomains of the BET family proteins have recently been shown as druggable targets for a wide array of human diseases, including cancer and inflammation. Here we review the structural and functional features of the bromodomains and their small-molecule inhibitors. Additional new insights provided herein highlight the landscape of the ligand binding sites in the bromodomains that will hopefully facilitate further development of new inhibitors with optimal affinity and selectivity.

摘要

溴结构域是保守的结构模块,负责识别组蛋白尾巴上的乙酰化赖氨酸残基以及其他与转录相关的蛋白质,如转录因子和辅助因子。由于其在染色质中有序基因转录调控中的重要功能,BET家族蛋白的溴结构域最近已被证明是包括癌症和炎症在内的多种人类疾病的可药物作用靶点。在此,我们综述了溴结构域及其小分子抑制剂的结构和功能特征。本文提供的其他新见解突出了溴结构域中配体结合位点的情况,有望促进具有最佳亲和力和选择性的新型抑制剂的进一步开发。

相似文献

1
Structural features and inhibitors of bromodomains.溴结构域的结构特征与抑制剂
Drug Discov Today Technol. 2016 Mar;19:3-15. doi: 10.1016/j.ddtec.2016.09.001. Epub 2016 Sep 22.
2
The bromodomain: from epigenome reader to druggable target.溴结构域:从表观基因组读取器到可成药靶点。
Biochim Biophys Acta. 2014 Aug;1839(8):676-85. doi: 10.1016/j.bbagrm.2014.03.011. Epub 2014 Mar 28.
3
Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.多溴-1-溴结构域在特定的乙酰赖氨酸位点与组蛋白H3结合。
Biochem Biophys Res Commun. 2007 Apr 13;355(3):661-6. doi: 10.1016/j.bbrc.2007.01.193. Epub 2007 Feb 9.
4
BET Bromodomain as a Target of Epigenetic Therapy.BET 溴结构域作为表观遗传治疗的靶点
Chem Pharm Bull (Tokyo). 2016;64(6):540-7. doi: 10.1248/cpb.c16-00225.
5
Structure and acetyl-lysine recognition of the bromodomain.溴结构域的结构与乙酰赖氨酸识别
Oncogene. 2007 Aug 13;26(37):5521-7. doi: 10.1038/sj.onc.1210618.
6
Bromodomains as targets for therapeutic intervention.作为治疗干预靶点的溴结构域
Drug Discov Today Technol. 2016 Mar;19:1-2. doi: 10.1016/j.ddtec.2016.09.002.
7
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.溴结构域-乙酰赖氨酸相互作用小分子抑制剂的开发与应用进展。
J Med Chem. 2012 Nov 26;55(22):9393-413. doi: 10.1021/jm300915b. Epub 2012 Sep 27.
8
Bromodomains and their pharmacological inhibitors.溴结构域及其药理学抑制剂。
ChemMedChem. 2014 Mar;9(3):438-64. doi: 10.1002/cmdc.201300434. Epub 2014 Feb 4.
9
Bromodomain inhibitors and cancer therapy: From structures to applications.溴结构域抑制剂与癌症治疗:从结构到应用
Epigenetics. 2017 May 4;12(5):323-339. doi: 10.1080/15592294.2016.1265710. Epub 2016 Dec 2.
10
Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.化学蛋白质组学分析溴结构域可广泛评估溴结构域抑制剂在活细胞中的作用。
J Am Chem Soc. 2019 Jul 24;141(29):11497-11505. doi: 10.1021/jacs.9b02738. Epub 2019 Jul 9.

引用本文的文献

1
BRD4 binds the nucleosome via both histone and DNA interactions.BRD4通过与组蛋白和DNA的相互作用结合核小体。
bioRxiv. 2025 May 30:2025.05.29.656846. doi: 10.1101/2025.05.29.656846.
2
Bromodomain-containing proteins in the unicellular eukaryote .单细胞真核生物中含溴结构域的蛋白质
Zool Res. 2025 May 18;46(3):538-550. doi: 10.24272/j.issn.2095-8137.2025.011.
3
Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.阿巴他龙(RVX - 208):一种用于治疗心血管、肾脏、神经、病毒和癌症疾病的潜在表观遗传疗法。
ACS Pharmacol Transl Sci. 2024 Feb 6;7(3):546-559. doi: 10.1021/acsptsci.3c00219. eCollection 2024 Mar 8.
4
The ncBAF Complex Regulates Transcription in AML Through H3K27ac Sensing by BRD9.ncBAF 复合物通过 BRD9 感知 H3K27ac 调控 AML 中的转录。
Cancer Res Commun. 2024 Jan 30;4(1):237-252. doi: 10.1158/2767-9764.CRC-23-0382.
5
Viral Hijacking of BET Proteins.病毒劫持 BET 蛋白。
Viruses. 2022 Oct 17;14(10):2274. doi: 10.3390/v14102274.
6
Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives.自身免疫性和炎症性疾病中表观遗传阅读蛋白和组蛋白去乙酰化酶的选择性靶向:最新进展与未来展望
J Pers Med. 2021 Apr 23;11(5):336. doi: 10.3390/jpm11050336.
7
Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.溴结构域和末端外结构域蛋白抑制剂治疗多种人类疾病。
Med Res Rev. 2021 Jan;41(1):223-245. doi: 10.1002/med.21730. Epub 2020 Sep 14.
8
Acetylation of H3K4, H3K9, and H3K27 mediated by p300 regulates the expression of GATA4 in cardiocytes.由p300介导的H3K4、H3K9和H3K27的乙酰化作用调节心肌细胞中GATA4的表达。
Genes Dis. 2018 Oct 15;6(3):318-325. doi: 10.1016/j.gendis.2018.10.002. eCollection 2019 Sep.
9
BET proteins: Investigating BRDT as a potential target for male contraception.BET 蛋白:探索 BRDT 作为男性避孕的潜在靶点。
Bioorg Med Chem Lett. 2020 Mar 15;30(6):126958. doi: 10.1016/j.bmcl.2020.126958. Epub 2020 Jan 21.
10
Vitamin C Sensitizes Melanoma to BET Inhibitors.维生素 C 使黑色素瘤对 BET 抑制剂敏感。
Cancer Res. 2018 Jan 15;78(2):572-583. doi: 10.1158/0008-5472.CAN-17-2040. Epub 2017 Nov 27.

本文引用的文献

1
GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain.GSK6853,一种用于抑制BRPF1溴结构域的化学探针。
ACS Med Chem Lett. 2016 May 9;7(6):552-7. doi: 10.1021/acsmedchemlett.6b00092. eCollection 2016 Jun 9.
2
RVX-297- a novel BD2 selective inhibitor of BET bromodomains.RVX-297——一种新型的BET溴结构域BD2选择性抑制剂。
Biochem Biophys Res Commun. 2016 Aug 12;477(1):62-67. doi: 10.1016/j.bbrc.2016.06.021. Epub 2016 Jun 6.
3
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.深入探究:BRD4、TAF1(2)、BRD9和CECR2溴结构域的可诱导结合构象
J Med Chem. 2016 Jun 9;59(11):5391-402. doi: 10.1021/acs.jmedchem.6b00264. Epub 2016 May 31.
4
Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.绘制化学染色质再激活图谱可鉴定 BRD4-TAF1 相互作用。
Nat Chem Biol. 2016 Jul;12(7):504-10. doi: 10.1038/nchembio.2080. Epub 2016 May 9.
5
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.探索对人类溴结构域与额外末端结构域(BET)蛋白首个溴结构域的选择性抑制作用。
J Med Chem. 2016 Feb 25;59(4):1634-41. doi: 10.1021/acs.jmedchem.5b01708. Epub 2016 Jan 6.
6
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.靶向 MYCN 驱动转录的 BET 溴结构域抑制。
Clin Cancer Res. 2016 May 15;22(10):2470-81. doi: 10.1158/1078-0432.CCR-15-1449. Epub 2015 Dec 2.
7
Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells.Atad2是胚胎干细胞中染色质动力学的多面促进因子。
J Mol Cell Biol. 2016 Aug;8(4):349-62. doi: 10.1093/jmcb/mjv060. Epub 2015 Oct 12.
8
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.三唑并苯二氮䓬类似物的新合成路线:拓展用于选择性溴化和末端外(BET)溴结构域抑制的“凹凸互补”方法的范围
J Med Chem. 2016 Feb 25;59(4):1492-500. doi: 10.1021/acs.jmedchem.5b01135. Epub 2015 Oct 1.
9
A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.人类溴结构域的一个亚群可识别丁酰赖氨酸和巴豆酰赖氨酸组蛋白肽修饰。
Structure. 2015 Oct 6;23(10):1801-1814. doi: 10.1016/j.str.2015.08.004. Epub 2015 Sep 10.
10
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.小分子抑制剂筛选确定了溴结构域抑制剂CPI203和硼替佐米在耐药性骨髓瘤中的协同活性。
Oncotarget. 2015 Aug 7;6(22):18921-32. doi: 10.18632/oncotarget.4214.